NEWS | alsv | Page 2 of 17

Companies in the News

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...

DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions

The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...

Federation Bio Administers First Dose in Phase 1 Clinical Trial

- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...

Escient Pharmaceuticals Announces $120 Million Series C Financing

Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and...

Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide

MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological...

Neumora Therapeutics Announces $112 Million Series B Financing

Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the...

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin

Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug...

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE

Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells,...